Researchers Discover First Lymphatic Vessel Growth Factor

May 30, 1997

An international research group including scientists from Finland and from the Massachusetts General Hospital (MGH) may have found the first factor regulating growth of lymphatic vessels. The discovery, which appears in the May 30 issue of Science, could lead to ways of repairing damage to lymphatic vessels and to better understanding of certain types of cancer.

The lymphatic system, the body's secondary circulatory system, is a network of fine vessels and nodes that collect a milky fluid called lymph from throughout the body and return it to the bloodstream near the heart. The fluid -- containing white blood cells, proteins and fats -- passes through lymph nodes, which filter out infectious bacteria, viruses and other foreign bodies. While the lymphatic system plays an important role in the body's immune function, many investigators believe it may be a conduit through which cancer spreads in the process called metastasis.

In recent years, scientists have identified several factors -- including vascular endothelial growth factors (VEGFs) -- that control the growth and proliferation of blood vessels, but until now no such factor controlling lymphatic vessels has been identified. The current article reports that a factor called VEGF-C, originally identified by researchers in the laboratory of Kari Alitalo, MD, PhD, at the University of Helsinki, appears to induce the enlargement of lymphatic vessels.

"This new factor eventually could make it feasible to program the behavior of cells lining the lymphatic vessels, possibly accelerating or inhibiting their growth," says Alitalo. "Applications could include improving healing after lymph nodes are removed in breast cancer surgery, preventing some tumors affecting the lymphatic system, or developing novel imaging methods to detect cancer in the lymphatic system."

The Finnish team created a group of transgenic mice that over-expressed the human gene for VEGF-C. Researchers in the laboratory of Rakesh Jain, PhD, at the MGH, found that the skin of these mice contained many unusually large vessels that functioned just like lymphatic vessels do.

The MGH researchers also found abundant messenger RNA for VEGF-C in the skin of the transgenic mice and located RNA for VEGF-C receptors in cells lining the abnormal vessels, observations which supported the relationship between the growth factor and the unusual vessels. The investigators also showed that the factor acted only on lymphatic vessels, having no effect on blood vessels, and that it induced vessels to grow larger -- up to twice the diameter of normal vessels -- but did not cause additional vessels to form.

Jain, whose research focuses on the physiology of tumors, notes: "A major problem in treating many solid tumors is that they have very high internal pressures, which makes it difficult to get drugs inside to kill the cancerous cells. This pressure may be related to the fact that, while tumors do grow new blood vessels, they do not develop functional lymphatic vessels, which normally drain fluids from the body's organs. One of our next steps will be to look at whether this new factor may be involved with the absence of functional lymphatics in tumors. The answer to that question could lead to better treatment methods."

Jain adds that VEGF-C may be only the first of a number of lymphatic growth factors to be discovered. "There may be additional factors involved in migration and growth of new vessels, activities not affected by VEGF-C. This is just the tip of the iceberg."

Jain is A.W. Cook Professor of Tumor Biology at Harvard Medical School and professor of Health Sciences and Technology at Massachusetts Institute of Technology. Alitalo also is a research professor at the Finnish Academy of Sciences.

The first authors of the Science paper are Michael Jeltsch, MSc, and Arja Kaipainen, MD, PhD, of Alitalo's lab in the Haartman Institute at University of Helsinki. Other coauthors at Helsinki are Vladimir Joukov, PhD, Xiaojuan Meng, MSc, Merja Lakso, PhD, and Heikki Rauvala, MD, PhD. Coauthors from the Steele Laboratory in the MGH Department of Radiation Oncology are Melody Swartz and Dai Fukumura, MD, PhD.

Contacts for Finnish researchers:
Kari Alitalo, MD, PhD
telephone: 011-358-9-191-26434
e-mail: kari.alitalo@helsinki.fi

Martti Turtola, Public Affairs
e-mail: martti.turtola@helsinki.fi
-end-


Massachusetts General Hospital

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.